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Abstract:  
 
The type 2 immune response controls helminth infection and maintains tissue homeostasis but 
can lead to allergy and fibrosis if not adequately regulated. We have discovered local tissue-
specific amplifiers of type-2 mediated-macrophage activation. In the lung, surfactant protein A 
(SP-A) enhanced IL-4-dependent macrophage proliferation and activation, accelerating parasite 
clearance and reducing pulmonary injury following infection with a lung-migrating helminth. In 
the peritoneal cavity and liver, C1q enhancement of type 2 macrophage activation was required 
for liver repair following bacterial infection, but resulted in fibrosis following peritoneal dialysis. 
IL-4 drives production of these structurally related defense collagens, SP-A and C1q, and the 
expression of their receptor, myosin 18A. These findings reveal the existence within different 
tissues of an amplification system needed for local type 2 responses. 
 
One Sentence Summary: Specific signals within the tissues are required to enhance IL-4Rα 
mediated macrophage activation and proliferation during infection and injury.  
 
Main Text:  
 
The type 2 cytokines IL-4 and IL-13, which signal through IL-4Rα, trigger a specialized 
macrophage phenotype (M(IL-4)) (1) that promotes control of helminth infection (2) and tissue 
repair (3, 4). M(IL-4)s also contribute to pathology associated with type 2 immunity, including 
allergy, asthma, and fibrosis (4).  However, little is known about tissue-specific factors that 
might promote both beneficial and detrimental actions of M(IL-4)s.  
 
In the lung, alveolar macrophages (aMφs), together with the respiratory epithelium, are covered 
by pulmonary surfactant, a lipid-protein network in which surfactant protein A (SP-A) 
constitutes the major protein component (5). SP-A is a versatile recognition protein (5) that is a 
member of a group of secreted soluble defense collagens that include the first component of the 
complement system (C1q), collectins (e.g., SP-A, SP-D, mannan-binding lectin), ficolins, and 
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adiponectin (6).  Because of its abundance and known role in immune defense (5), we asked 
whether SP-A was involved in the local regulation of M(IL-4) effector function in the lung. 
 
M(IL-4)s have a critical role in lung repair following infection with the lung-migrating nematode 
Nippostrongylus brasiliensis (3).  We therefore infected WT, IL-4Rα-deficient and SP-A-
deficient mice with N. brasiliensis infective larvae. Larvae migrate to the lung where they mature 
for ∼2 days, and reach the small intestine by 3 days post infection (p.i.).  The type 2 response 
peaks 6-7 days after inoculation. We observed an up-regulation of SP-A protein (Fig. 1A) and 
mRNA (Fig. S1A) in lungs of N. brasiliensis infected C57BL/6 mice at 6 days p.i, which was 
dependent on IL-4Rα.  Consistent with a role for SP-A during type 2 immunity to nematode 
infection, SP-A-deficient mice had greater adult worm burdens (Fig. 1B) and egg output (Fig. 
S1B), and significantly impaired lung repair processes (Fig. 1C, D) than wild type (WT) mice.  
The failure to heal was associated with a failure to up-regulate tissue-repair related gene Col1a1 
(Collagen, type I, alpha 1) (Fig. 1E) and increased expression of Mmp12, an extracellular matrix-
degrading enzyme (Fig. 1F).  Greater lung damage in SP-A-deficient mice was indicated by 
increased numbers of red blood cells and neutrophils in bronchoalveolar lavage (BAL) at 6 days 
p.i (Fig. 1G, H).  The absence of SP-A resulted in reduced expression of the M(IL-4) proteins 
RELMα (Fig. 1I), Ym1, and arginase (Fig. S1C,D) in aMφs.  Secretion of RELMα and Ym1 
protein into the alveolar fluid (Fig. S1E) was also reduced in SP-A-deficient mice compared 
with WT mice. 
 
Consistent with the known ability of IL-4 to cause macrophage proliferation during helminth 
infection (7), aMφs from WT mice exhibited significant proliferation (Fig. 1J, K) and increased 
aMφs numbers (Fig. S1F) 6 days following N. brasiliensis infection.  However, SP-A-deficient 
mice failed to exhibit significantly enhanced aMφ proliferation (Fig. 1J, K) resulting in fewer 
total macrophage numbers relative to WT mice (Fig. S1F).  There was no evidence that 
differences were caused by a failure of SP-A-deficient mice to mount appropriate ILC2, TH2 
(Fig. S1G & H) or local type 2 cytokine responses (Fig. S1I).  Importantly, aMφs from 
uninfected SP-A-deficient mice were normal in number, phenotype and ability to respond to IL-4 
ex vivo (Fig. S2A-D).  
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To ascertain if defects in SP-A-deficient mice were caused by defective IL-4Rα responsiveness 
in vivo, WT and SP-A-deficient mice were injected intra-peritoneally (ip) with IL-4 complex 
(IL-4c). IL-4c delivery increased the amount of SP-A protein in BAL (Fig. 1L) in WT mice and 
induced M(IL-4) markers and proliferation in aMφs isolated from BAL (Fig. 1M, N and S3A-C) 
of WT but not SP-A-deficient mice, reflected by diminished secretion of RELMα and Ym1 to 
the alveolar fluid in SP-A-deficient mice (Fig. S3D). IL-4c delivery decreased IL-4Rα 
expression in both WT and SP-A-deficient aMφs (Fig. S3E). 
Enhancement of M(IL-4)s may underlie the previously reported contribution of SP-A to tissue 
integrity in other models of acute lung injury (8, 9).  The pro-type 2 effects we report here 
contrast with reports that associate SP-A with protection in asthma (10).  However, in addition to 
promoting M(IL-4) and proliferation of macrophages, the anti-inflammatory properties of SP-A 
(5, 6, 8, 9, 11) may suppress the strong inflammatory responses that are responsible for more 
severe asthma.  Our data are supported by the finding that SP-D-deficient mice, which lack SP-A 
(12), also have reduced M(IL-4) responsiveness (13).  
To determine whether SP-A acts directly on aMφs, we first tested the ability of adherence-
purified macrophages from the alveolar and peritoneal spaces to proliferate in vitro in response 
to 1 µg/ml of IL-4; aMφ exhibited significant proliferation, but peritoneal macrophages (pMφ) 
failed to proliferate despite expressing M(IL-4) activation markers (Fig. S4A).  We then tested 
the ability of SP-A to enhance IL-4 treatment and included C1q as a control because it is a 
defense collagen structurally homologous to SP-A (5, 6).  We found that SP-A, but not C1q, 
significantly boosted IL-4-mediated aMφ proliferation and M(IL-4) markers (Fig. 2A).  IL-4Rα-
deficient aMφ showed no proliferation or activation when stimulated with IL-4 (1 µg/ml) in the 
absence or presence of SP-A (Fig. S4B).  Notably, SP-A significantly enhanced proliferation and 
activation induced by IL-4 in both human (Fig. S4C) and rat aMφs (Fig. S4D).  
 
To our surprise C1q, but not SP-A, significantly increased IL-4-mediated proliferation and M(IL-
4) marker expression in pMφ (Fig. 2A).  To verify these findings in vivo, IL-4c was delivered to 
C1qa-deficient mice.  Consistent with the in vitro studies, mice lacking C1q exhibited reduced 
IL-4-dependent activation and proliferation in pMφ but not aMφ (Fig. 2B).  Similar to SP-A in 
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the lung (Fig. 1L), C1q levels increased in the peritoneal fluid after IL-4c delivery (Fig. S5A), 
indicating that IL-4 drives production of a local signal to amplify its effect on tissue 
macrophages.  Importantly, the pMφ phenotype, number, and ability to respond to IL-4 ex vivo 
are normal in C1qa-deficient mice (Fig. S5 B-F).  Thus, SP-A and C1q were induced by IL-4 in 
the lung and peritoneal cavity, respectively, where they acted to enhance proliferation and M(IL-
4) activation in a tissue-specific manner.   
 
To determine which receptor mediates SP-A effects on IL-4-stimulated aMφs, we inhibited 
known receptors for SP-A (5).  We observed that the blockade of Myosin18A (Myo18A, aka SP-
R210), but not signal inhibitory regulatory protein α (SIRPα) or calreticulin (aka cC1qR), 
abrogated SP-A-mediated enhancement of IL-4-induced arginase activity in rat aMφs (Fig. S6A).  
Blockade or RNA silencing of Myo18A consistently abolished SP-A-mediated enhancement of 
IL-4-induced proliferation and activation of mouse (Fig. 2C), human (Fig. S6B) and rat (Fig. 
S6C) aMφs.  Myo18A is an unconventional myosin that does not operate as a traditional 
molecular motor, having both intracellular and cell-surface locations (14), and was recently 
defined as CD245 (15).  Immune activation results in Myo18A localization on the cell surface, 
where it binds to the collagen-like domain of SP-A (6, 16) and we confirmed that an intact 
collagen-like domain is required to enhance IL-4-mediated type 2 responses (Fig. S6D). 
 
Because C1q is structurally homologous to SP-A in its supra-trimeric assembly and collagen tail 
(5, 6), we addressed whether Myo18A was also responsible for the actions of C1q.  Indeed, 
blockade of Myo18A prevented C1q enhancement of IL-4 driven activation and proliferation of 
pMφ (Fig. 2C).  In vitro, IL-4 promoted Myo18A localization on the cell surface of both aMφ 
and pMφ (Fig. S7A, B), which was maximal 24 hours after stimulation. Cell surface expression 
of Myo18A was similarly observed in vivo following IL-4c delivery (Fig. S7 C, D), independent 
of the presence or absence of SP-A or C1q.  We confirmed the role of Myo18A in vivo by 
intranasal or intraperitoneal delivery of anti-Myo18A antibody.  Receptor blockade significantly 
reduced IL-4-induced proliferation and M(IL-4) activation of aMφ and pMφ (Fig. 2D), as well as 
secretion of RELMα and Ym1 to the alveolar and peritoneal fluid (Fig. S7E, F).  Thus, Myo18A 
receptor blockade in the lung or peritoneal cavity phenocopied SP-A or C1qa deficiency, 
respectively.  Together these data indicate that Myo18A is a common receptor or co-receptor for 
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defense collagens present on aMφs and pMφs, which determines macrophage capacity to respond 
to IL-4 and whose cell surface expression is itself induced by IL-4. Myo18A lacks a trans-
membrane domain (14), and thus must act in concert with transmembrane co-receptors for signal 
transduction that likely impart tissue-specificity. 
 
The relevance of C1q as a local factor to enhance type 2 responses is supported by the fact that 
unlike most other complement components, the majority of C1q is produced by myeloid cells in 
peripheral tissues (17).  To determine the physiological relevance of C1q in this context, we 
evaluated its role in a murine model of peritoneal fibrosis (18). Peritoneal fibrosis is a frequent 
and serious consequence of peritoneal dialysis (19) associated with alternatively activated 
macrophages in both humans and mice (18-20).  We administered Dianeal-PD4, a clinically-used 
lactate-based dialysate, every other day for 28 days to WT, C1qa-, and IL-4Rα-deficient mice.  
In WT, but not in C1qa-deficient mice, Dianeal-PD4 treatment provoked the induction of C1q 
(Fig. 3A) and morphologic changes in tissue sections of the parietal peritoneum, showing 
significant enlargement of the submesothelial zone caused by collagen deposition (Fig. 3B, C).  
Dianeal-PD4 treatment induced markers of fibrosis including collagen mRNAs (Col1a1 and 
Col3a1) (Fig. 3D and Fig. S8A), alpha-smooth muscle actin (Acta2) (Fig. 3E), and vascular 
endothelial growth factor (Vegf) (Fig. S8B).  Significant upregulation of these markers was not 
observed in C1qa-deficient mice.  Conversely, Mmp12 mRNA was up-regulated in C1qa-
deficient mice relative to WT mice (Fig. S8C) consistent with monocyte infiltration (Fig. S8D) 
(21), and an anti-inflammatory role for C1q (22).  Dianeal-PD4 treatment also induced 
intracellular expression and protein secretion of the M(IL-4) markers RELMα, Ym1, and Arg 
(Fig. 3F-H) and moderate proliferation of pMφs (Fig. 3I) in WT but not C1qa-deficient mice. 
Despite the clear induction of M(IL-4) markers by PD4 delivery and their dependence on C1q, 
responses of IL-4Rα-deficient mice were equivalent to WT mice (Fig. 3A-I and Fig. S8 A-D).  
Although initially surprising, Dianeal-PD4 is a lactate-based solution, and lactate can induce 
M(IL-4) markers by acting downstream of IL-4Rα through stabilization of HIF1α protein (23).  
Indeed, we observed that the induction of proliferation and M(IL-4) markers following Dianeal-
PD4 delivery was essentially absent in mice lacking HIF1α in macrophages (Fig. S9).  Together, 
our data indicate that C1q significantly amplifies peritoneal fibrosis by promoting a type 2 
macrophage phenotype driven by lactate and dependent on HIF1α.  These results are consistent 
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with human studies in which C1q is strongly associated with increased fibrosis of skeletal muscle 
(24). 
 
Critically, we needed to ascertain whether C1q functioned as a type 2 amplifier in tissues beyond 
the peritoneal cavity and settings that are dependent on IL-4Rα.  We thus assessed Myo18A 
expression on the cell surface of resident macrophages from mice treated with or without IL-4c 
(Fig. 4A).  Consistent with our functional data, Myo18A was expressed in macrophages from the 
lung and peritoneal cavity, as well as in liver, spleen and adipose tissue, and significantly 
increased by IL-4 exposure.  In contrast, there was minimal Myo18A on pleural cavity 
macrophages, which explained our failure to identify a role for C1q in the pleural cavity 
following IL-4c delivery (Fig. S10).  As predicted by the Myo18 expression data, we found that 
macrophages from the liver of C1qa-deficient mice had significantly lower levels of proliferation 
and M(IL-4) activation compared with WT mice following IL-4c delivery (Fig. 4B).  
Importantly, we observed C1q upregulation in the liver of IL-4c treated mice (Fig. 4C).  Of 
relevance, the number and phenotype of liver macrophages are normal in C1qa-deficient mice 
(Fig. S11).  Antibody blockade of Myo18A following IL-4 treatment of isolated liver 
macrophages verified that C1q generated its effects through Myo18A (Fig. S12).  We thus 
sought a model in which M(IL-4)s in the liver played a substantive role.  
 
Infection of the liver by the Gram-positive bacteria Listeria monocytogenes causes necroptotic 
death of resident liver macrophages (Kupffer cells) followed by recruitment of monocytes, which 
control L. monocytogenes infection (25) and repopulate the liver macrophage population (26).  
Following an initial type 1 response, the type 2 response begins at 3 days p.i. with IL-4-mediated 
activation and proliferation of liver macrophages acting to repair infection damage (26).  To 
ascertain the relevance of C1q and confirm the role of IL-4Rα in this process, we infected WT, 
C1qa- and IL-4Rα-deficient mice with L. monocytogenes and performed sample analysis 3.5 
days later. Infection resulted in IL-4Rα-dependent up-regulation of C1q mRNA in liver (Fig. 
4C) while enhanced expression of RELMα and Ym1 by liver macrophages (Fig. 4D and Fig. 
S13A) and macrophage proliferation (Fig. 4E and Fig. S13B) were dependent on both IL-4Rα 
and C1q.  Consistent with the requirement for basophil-derived IL-4 in L. monocytogenes-
induced liver macrophage proliferation (26), we observed increases in IL-4 and IL-13 cytokines 
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in liver homogenates (Fig. S13C).  C1q and IL-4Rα deficiency were associated with increased 
liver injury as assessed by liver transaminases in blood (Fig. 4F) and a failure to up-regulate 
tissue-repair related genes (Acta2 and Col1a1) (Fig. 4G).  Notably, at 3.5 days p.i., liver bacterial 
burden was higher in WT than in C1qa- or IL-4Rα-deficient mice (Fig. 4H). Gene-deficient 
mice had increased numbers of recruited monocytes (Fig. 4I) and higher iNOS expression in 
monocytes (CD11b+ Ly6C+) and liver macrophages (CD11b+ F4/80+) (Fig. S13 D, E) but pro-
inflammatory cytokines in liver homogenates were comparable (Fig. S13F). These data suggest 
that C1q, through its ability to orchestrate IL-4Rα-dependent type-2-mediated responses, 
decreases the bactericidal capacity of monocyte-derived macrophages, but also limits liver injury 
and promotes the return to homeostasis (Fig. 4D-I and Fig. S13). 
 
M(IL-4)s have recently emerged as important players in homeostatic processes (27), but IL-4Rα-
dependent pathways are amplified during helminth infection with uncontrolled amplification 
leading to fibrosis (4, 28, 29).  Our data show that IL-4 drives production of local specific factors 
(SP-A and C1q) and expression of their receptor (Myo18A) on the macrophage surface for full 
M(IL-4) activation and proliferation (Fig S14) .  These findings reveal the existence within 
distinct tissues of an amplification system needed for type 2 function.  SP-A and C1q are 
typically produced by alveolar epithelial type II and myeloid cells, respectively, indicating that 
several different cell types must respond to IL-4 for signal amplification.   
 
The study raises a number of critical questions.  What are the Myo18A co-receptors that mediate 
tissue-specificity?  What factors negatively regulate or stop the positive M(IL-4) loop?  What are 
the intracellular signaling pathways regulated by Myo18A and its co-receptors? Critically, SP-A, 
C1q, and Myo18A are highly conserved across mammalian species, and we have shown the 
ability of SP-A and Myo18A to enhance human alveolar M(IL-4) proliferation.  
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FIGURE LEGENDS 
 
Fig. 1. Higher worm burden, greater nematode-induced lung damage and reduced IL-4-
induced proliferation and activation in mice lacking SP-A. Samples were assessed 6 days 
after N. brasiliensis (Nb) infection. (A) SP-A protein expression in lung tissue of WT and IL-
4Rα-/- mice. (B) Adult larvae in the small intestine. (C) Lung damage, quantified by ‘mean linear 
intercept’ from micrographs of H&E stained lung sections, and (D) microscopy of H&E stained 
lung sections (scale bars, 500 µm) in WT and SP-A-/- mice. (E) Amplification of Col1a1- and (F) 
Mmp12-encoding mRNA in lung tissue. Number of (G) red blood cells and (H) neutrophils 
isolated in BAL. Expression of (I) RELMα by aMφ from BAL. (J) BrdU incorporation and (K) 
Ki67 expression by aMφ from BAL. Data are representative from two independent experiments 
(mean ± SEM; naïve: 3 mice, Nb: 6 mice). (L-N) WT and SP-A-/- mice treated with 5µg IL-4c 
(i.p.) at days 0 and 2 and analyzed at day 4. (L) Relative SP-A levels in BAL (representative 
western blot shown) of WT mice treated with IL-4c or PBS. (M) RELMα expression and (N) 
BrdU incorporation in aMφ. Data pooled from three independent experiments (means ± SEM) 
(PBS: 9 mice, IL-4c: 11 mice). ANOVA followed by the Bonferroni multiple-comparison test 
was used. *p < 0.05, **p < 0.01, and ***p < 0.001 when compared with the untreated/uninfected 
group. °p < 0.05, °°p < 0.01 and °°°p < 0.001 when WT vs. SP-A-/- groups are compared.  
 
Fig 2. SP-A and C1q act through Myo18A to enhance IL-4-induced proliferation and 
activation of alveolar and peritoneal macrophages, respectively. (A) Murine macrophages 
were treated with IL-4 in the presence or absence of SP-A or C1q. BrdU incorporation and Ym1 
secretion are shown. (B) For aMφs (red), 5 µg IL-4c was delivered ip at days 0 and 2, and BAL 
cells analyzed at day 4. For pMφs (blue), 1 µg IL-4c was delivered ip at day 0, and peritoneal 
cells analyzed at day 1: BrdU incorporation and RELMα expression are shown. (C) Murine 
macrophages were treated with anti-Myo18A or rabbit IgG plus either IL-4+SP-A (aMφ) or IL-
4+C1q (pMφ). BrdU incorporation and Ym1 secretion are shown.  (D) Concurrently with IL-4c 
delivery, some WT mice were treated intra-nasally or ip with either anti-Myo18A or rabbit IgG 
antibody. BrdU incorporation and RELMα expression are shown in aMφs and pMφs. All 
statistical analysis was performed by ANOVA followed by the Bonferroni multiple-comparison 
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test.  (A and C) Results are presented as means (± SEM) from three different cell cultures with at 
least three biological replicates.  *p < 0.05, **p < 0.01, and ***p < 0.001, when compared with 
untreated cells; °p < 0.05, °°p < 0.01, and °°°p < 0.001, when SP-A+IL-4- or C1q+IL4-treated 
are compared with IL-4-treated; ##p < 0.01, and ###p < 0.001, the effect of anti-Myo18A 
antibody on cells treated with SP-A+IL-4 or C1q+IL4.  (B and D) Data were pooled from three 
independent experiments (means ± SEM) (PBS: 6 mice, other groups: 9 mice). *p < 0.05, **p < 
0.01, and ***p < 0.001, when compared with PBS treated mice; °p < 0.05, when WT vs. C1qa-/- 
mice treated with IL-4c are compared (B); °p < 0.05, °°p < 0.01, and °°°p < 0.001 when anti-
Myo18A vs rabbit IgG treatment is compared in IL-4c-treated mice (D). 
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Fig. 3. C1q enhances peritoneal fibrosis induced by a lactate dialysate. WT, C1qa-/- or IL-
4Rα-/- mice were either untreated (C) or injected ip with Dianeal PD-4 every other day for 28 
days. Samples were analyzed a day after the last delivery. (A) Total amount of C1q in the 
peritoneal washes was determined by ELISA. (B) Quantification of the thickness of the 
submesothelial compact zone from (C) microscopy of Masson’s trichrome stained parietal 
peritoneum slices (scale bars, 0.1 mm). Amplification of (D) Col1a1- and (E) Acta2 -encoding 
mRNA in peritoneal tissue. Expression of (F) RELMα, (G) Ym1, (H) Arg and (I) Ki67 by 
pMφs. Results are representative from two independent experiments (means ± SEM) (untreated: 
3 mice, PD4: 6 mice). ANOVA followed by the Bonferroni multiple-comparison test or 
Student’s t-test (A) was used. *p < 0.05, **p < 0.01, and ***p < 0.001 when compared with 
control group; °p < 0.05, °°p < 0.01, and °°°p < 0.001 when WT vs. C1qa-/- mice treated with 
Dianeal PD-4 are compared. 
 
Fig. 4. C1q is required for appropriate macrophage activation in the liver during Listeria 
monocytogenes infection. (A, B, C) WT or C1qa-/- mice received 1 µg IL-4c (ip) at day 0, and 
samples were analyzed at day 1. (A) Myo18A expression on the surface of resident macrophages 
(identified as described in the methods) from the indicated tissues. (B) BrdU incorporation and 
RELMα expression of liver macrophages. (C) (upper panel) IL-4-induced amplification of C1q-
encoding mRNA in the liver. (C-I) WT, C1qa-/-, or IL-4Rα-/- mice were left uninfected or 
received intravenous infection with 104 L. monocytogenes (Lm) c.f.u., and samples were 
assessed at 3.5 days p.i. (C) (lower panel) L. monocytogenes-induced amplification of C1q-
encoding mRNA. (D) Expression of RELMα by liver macrophages. (E) BrdU incorporation by 
liver macrophages.  (F) Quantification of ALT and AST in serum. (G) Amplification of Acta2- 
and Col1a1-encoding mRNA in the liver.  (H) Liver bacterial load. (I) Number of monocytes in 
liver single cell suspensions. Data are representative from two independent experiments (mean ± 
SEM; naïve: 4 mice, Lm: 5 mice). ANOVA followed by the Bonferroni multiple-comparison test 
was used. *p < 0.05, and ***p < 0.001, when compared with the uninfected group; °p < 0.05, °°p 
< 0.01, and °°°p < 0.001 when WT vs. C1qa-/- or IL-4Rα-/- infected groups are compared. 
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Materials & Methods 
 
Proteins  
Surfactant protein A was isolated from BAL of patients with alveolar proteinosis 
using a sequential butanol and octylglucoside extraction (11, 30-33). The purity of 
SP-A was checked by one-dimensional SDS-PAGE in 12 % acrylamide under 
reducing conditions and mass spectrometry. The oligomerization state of SP-A was 
assessed by electrophoresis under non-denaturing conditions (31-33), electron 
microscopy (33), and analytical ultracentrifugation as reported elsewhere (32). SP-A 
consisted of supratrimeric oligomers of at least 18 subunits. Each subunit had a 
relative molecular mass (Mr) 36 kDa. Recombinant human SP-A1 (SP-A1hyp) was 
expressed in insect cells and purified from the medium by mannose affinity 
chromatography (31, 32). The stability of SP-A1hyp collagen domain was assessed by 
circular dichroism (31, 32) and differential scanning calorimetry (32). The 
oligomerization state of SP-A1hyp was evaluated by electrophoresis under non-
denaturing conditions (31, 32) and analytical ultracentrifugation (32). SP-A1hyp 
consists of trimers and hexamers. The endotoxin content of native or recombinant 
human SP-A was < 0.1 endotoxin units /mg of SP-A as determined by Limulus 
amebocyte lysate assay (GenScript, Piscataway, New Jersey). Levels of mouse SP-A 
from BAL, pleural exudate, or lung tissue were detected by western-blot analysis as 
reported elsewhere (11, 30-33). Native human C1q was obtained from Abcam 
(Cambridge, UK). C1q consists of octadecameres with a Mw 410 kDa. 
 
Experimental animals  
C57BL/6 WT and gene-targeted mice were used in this study. SP-A (Sftpa1-/-) (34), 
C1q (C1qa-/-) (35), IL-4Rα (Il4ra-/-) (36) and myeloid-specific HIF-1α 
(Hif1aflox/flox;LysMcre+/−) (37) deficient mice and WT mice were bred and maintained 
at the University of Edinburgh in specific-pathogen free conditions. Sex-matched 
mice were 6-8-weeks old at the start of the experiment, and all mice were housed in 
individually ventilated cages. Sftpa1-/- and Sftpa1+/+ littermates were genotyped using 
specific primers (Supplementary Table 1). Mice were not randomized in cages, but 
each cage was randomly assigned to a treatment group. Investigators were not blinded 
to mouse identity during necropsy; however, the analysis of adult worms, eggs in 
faeces, lung and peritoneal pathology were performed in a blinded fashion. 
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Experiments were performed in accordance with the United Kingdom Animals 
(Scientific Procedures) Act of 1986 and the Spanish guidelines for experimental 
animals. All researchers were accredited for animal handling and experimentation by 
the UK and Spanish government Home Office. Dispensation to carry out animal 
research at The University of Edinburgh was approved by the University of 
Edinburgh Animal Welfare and Ethical Review Body and granted by the UK 
government Home Office; as such all research was carried under the project licenses 
PPL60/4104, PPL70/8548 and PPL70/8470. Sample size was calculated on the basis 
of the number of animals needed for detection of macrophage proliferation in WT 
mice, based on published experiments (38-40). Data was not excluded under any 
circumstances.  
 
Sprague Dawley rats (~350 g) were purchased from Harlan (Indianapolis, IN). All 
animal experiments were fully compliant with the regulations set by the local ethical 
committee. Animals were treated according to the Directive 2010/63/EU of The 
European Parliament and the Spanish act RD53/2013 of 8th February 2013 on 
protection of animals used for experimentation and other scientific purposes. 
 
Nippostrongylus brasiliensis infection 
Mouse-adapted N. brasiliensis was maintained by serial passage through C57BL/6 
mice, as described previously (41). Mice were infected subcutaneously with 250 or 
400 N. brasiliensis third-stage larvae. Analysis of samples was performed at day 6 
post-infection. Egg output was analyzed in faeces and adult worm burden was 
determined by removing the small intestine and exposing the lumen by dissection. For 
macrophage proliferation analysis, mice were injected with 100 µl of 10 mg/ml BrdU 
in Dulbecco’s phosphate buffered saline 3h before experimental end-point. The lungs 
and pleural cavities were washed to obtain the bronchoalveolar lavage (BAL) and 
pleural exudate. Subsequently, the right lung was perfused and fixed for histology. 
Alternatively, one section of the left lung was stored for mRNA quantification; 
another section was homogenized to obtain single cell suspensions for flow cytometry 
analysis, and a third section was stored for SP-A quantification. In this case, lung 
tissue was homogenized in HBSS containing protease inhibitor cocktail (Sigma). SP-
A was detected in both lung homogenates and BAL by western blot analysis using an 
anti-mouse SP-A (GeneTex, Inc, Irvine, CA). SP-A levels were normalized by BAL 
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volume or GAPDH. Only samples on which the same BAL volume was recovered 
were used for SP-A quantification.  
BAL cells were obtained by washing the lung with Dulbecco’s phosphate buffered 
saline containing 0.5% BSA (m/v). Cells from pleural or peritoneal exudate were 
obtained by washing either pleural or peritoneal cavity with RPMI 1640 containing 2 
mM L-glutamine, 200 U/ml penicillin, 100 µg/ml streptomycin. Single cell 
suspensions of thoracic lymph node tissue were re-stimulated ex vivo with N. 
brasiliensis excretory secretory antigen (42) (1 µg/ml) or anti-CD3 (1 µg/ml), and cell 
supernatants were analysed by ELISA 72 h later.  
 
Listeria monocytogenes infection 
Listeria monocytogenes infections were performed as previously described (26). 
Briefly, frozen stocks of L. monocytogenes (Lm10403s) were thawed and then diluted 
in fresh Brain-Heart-Infusion (BHI) medium to reach mid-log growth phase. Mice 
were intravenously injected via the lateral tail vein with 1 x104 L. monocytogenes 
c.f.u. suspended in 200 µl of PBS. Analysis of samples was performed at day 3.5 
post-infection. The livers were perfused in situ with phosphate-buffered saline (PBS) 
before collection. For macrophage activation and proliferation analysis, mice were 
injected with 100 µl of 10 mg/ml BrdU in Dulbecco’s phosphate buffered saline 3h 
before experimental end-point. One section of the liver was homogenized to obtain 
single cell suspensions for flow cytometry analysis, a second section of the liver was 
stored for mRNA quantification; a third section was stored for cytokine quantification 
by ELISA; and a fourth section was homogenized to analyze bacterial burden. To 
analyze cytokine secretion by ELISA, the liver tissue was weighed before 
homogenization in Hank’s balanced salt solution (HBSS) containing protease 
inhibitor cocktail. To quantify bacterial burden, serial dilutions of cell suspensions in 
PBS were plated on BHI agar plates. After 24 hr of incubation at 37°C, colony-
forming units were counted. To analyze liver damage, blood was collected from the 
inferior vena cava and alanine transaminase (ALT) and aspartate transaminase (AST) 
levels were determined in the serum.   
 
Peritoneal fibrosis model  
Peritoneal fibrosis was induced by continuous administration of Dianeal PD-4 
(Baxter, Deerfield, Illinois), as described previously (18) with slight modifications. 
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Mice received a total of 5 or 14 injections of 500 µl (~200 ml/kg) of Dianeal PD-4 
(ip) on alternate days. Animals were sacrificed a day after the last delivery. The right 
section of the parietal layer of the peritoneum was collected for histology analysis. 
The left section of the peritoneum was stored in RNAlater for subsequent analysis. 
Peritoneal macrophages were isolated from the peritoneal cavity as described below. 
Note: Although timing of macrophage activation and proliferation in this model 
varied slightly between males and females all animals developed peritoneal fibrosis 
after 14 injections.  
 
Histology  
The right lung lobes were perfused and fixed with 10% neutral buffered formalin, 
incubated overnight and transferred to 70% ethanol. Lungs were paraffin-embedded, 
sectioned and stained with H&E. Linear means intercept (Lmi) method was used to 
quantify emphysema like damage (43). To calculate Lmi, 20 random non-overlapping 
fields (magnification x200) per H&E stained lung sample were taken. Six horizontal 
lines were drawn across each image (ImageJ 1.44) and the total number of alveolar 
wall intercepts counted per line. The length of each line was then divided by the 
number of intercepts to give the Lmi value. Images that included large bronchi and 
vessels were avoided and analysis was performed in a blinded and randomised 
fashion. With respect to histological analysis of the peritoneum tissue, the right 
parietal layer of the peritoneum was fixed with 10% neutral buffered formalin, 
incubated overnight and transferred to 70 % ethanol. Subsequently, peritonea were 
paraffin-embedded, sectioned and stained for Masson’s trichrome. The thickness of 
the submesothelial compact zone was measured using ImageJ and this value was used 
to score the extent of peritoneal fibrosis. Five independent (×200) images were taken 
to examine the overall section. For each image, six horizontal lines were randomly 
drawn across the submesothelial compact zone to measure its thickness and the 
average value of each sample was used for analysis.  
 
IL-4 complex delivery and in vivo blocking of Myo18A 
IL-4 was delivered as a 2:1 molar ratio of recombinant mouse IL-4 (Peprotech) and 
anti-IL-4 mAb (clone 11B11; BioXcell,) (38, 39). For pulmonary macrophage 
analysis, mice were injected ip with IL-4 complex (IL-4c) containing 5 µg of IL-4 and 
25 µg of 11B11, or PBS vehicle control on days 0 and 2. Simultaneously, 50 µg of 
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anti-Myo18A neutralizing antibody (provided by Dr Zissis C. Chroneos (16)) or 
Rabbit IgG (R&D Systems) were delivered intra-nasally on days 2 and 3, and samples 
were collected on day 4. For studies of peritoneal macrophages, liver macrophages, 
and other tissue resident macrophage populations, mice received a single ip injection 
of 1 µg of IL-4 and 5 µg of 11B11, or PBS vehicle control. Anti-Myo18A 
neutralizing antibody (16) or Rabbit IgG (100 µg) was delivered 2 hours before IL-4c 
injection and samples were collected 24 hours later.  Mice received a pulse of BrdU 3 
h before experimental end-point. Bronchoalveolar, pleural and peritoneal cavity 
lavages as well as lung and liver tissue collection were performed as described above.  
 
RNA extraction and quantitative real-time PCR 
A section of the left lung, liver or parietal peritoneum was stored in RNAlater 
(Ambion, Carlsbad, CA). Tissue was homogenised in Trizol (Invitrogen) with a 
TissueLyser (Qiagen, Hilden, Germany). Similarly, human alveolar macrophages 
were collected with Trizol, and RNA was prepared according to manufacturer’s 
instructions. Reverse transcription was performed using 1 µg of total RNA, 50 U 
Tetro reverse transcriptase (Bioline, London, UK), 40 mM dNTPs (Promega, 
Fitchburg, WI), 0.5 µg Oligo dT15 (Roche, Basel, Switzerland), and RNasin inhibitor 
(Promega). Transcript levels of genes of interest were measured by real-time PCR 
with the Lightcycler 480 II system (Roche) using SYBR Green I Master kit and 
specific primers (Supplementary Table 2) as previously described (43). Transcript 
levels of C1qa mRNA were measured using Taqman Master kit and the primers 
Mm00432142 (Applied Biosystems). PCR amplification was analyzed using 2nd 
derivative maximum algorithm (LightCycler 480 Sw 1.5, Roche) and the expression 
of the gene of interest was normalized to a housekeeping gene Rn18s, Rpl13a, or 
GAPDH. In the case of human alveolar macrophages, cells from at least 8 humans 
were used for all groups. 
 
Flow Cytometry 
Single cell suspensions from left lung, liver and other tissues were prepared by 
digesting with 80 U/ml DNase (Life Technologies, Carlsbad, California) combined 
with 0.2 U/ml liberase TL (Roche) in HBSS at 37°C for 30 minutes. In some cases, 
liberase was combined with collagenase B (0.2 mg/ml) and D (0.4 mg/ml) (Roche). 
Tissue was homogenized by forcing through a 70 µM cell strainer. Cells from tissue 
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homogenates, BAL, pleural exudate, and peritoneal cavity exudate were treated with 
red blood cell lysis buffer (Sigma) and counted using an automated cellometer T4 
(Peqlab). Cells were incubated with Fc block (CD16/CD32 and mouse serum) (BD 
Biosciences, Franklin Lakes, NJ) and stained with fluorescent conjugated antibodies 
to CD19 (clone 6D5; Biolegend, Cambridge, UK), Siglec F (clone E50-2440; BD 
Biosciences), Ly6G (clone 1A8; Biolegend), CD3 (clone 17A2; Biolegend), CD45.2 
(clone 104; Biolegend), Ly6C (clone HK1.4; Biolegend), CD11c (clone N418; 
Biolegend), CD11b (clone M1/70; Biolegend), F4/80 (clone BM8, eBiosciences, 
Hatfield, UK), I-A/I-E (MHCII) (clone M5/114.15.; eBiosciences), CD102 (clone 
3C4 (MIC2/4); Biolegend), GATA6 (ref. D61E4; Cell Signaling, Danvers, MA), 
TER119 (clone TER-119; Biolegend), CD4 (clone RM4-5; Biolegend), FcεR1 (clone 
MAR-1; Biolegend), NK-1.1 (clone PK136; Biolegend), CD90.2 (clone 30-H12; 
Biolegend), ICOS (clone C398.4A; Biolegend) and unconjugated anti-Myo18A 
antibody  (16) (5 µg/ml) or isotype control followed by secondary reagents 
(Invitrogen). The following surface markers identified alveolar macrophages: lineage- 
(CD19, Ly6G, CD3 and TER119), Ly6C-, CD45.2+, CD11c+ and SiglecF+. Peritoneal, 
pleural, and liver macrophages as well as other tissue resident macrophages were 
identified as lineage- (CD19, SiglecF, Ly6G and CD3), CD11c-, Ly6C-, CD45.2+, 
CD11b+ and F4/80+ or high (38). ILC2 cells were identified as lineage- (CD3, CD11b, 
CD11c, FcεR1, CD19, and NK1.1) CD90.2+ ICOS+ CD45.2+ cells. T helper cells 
were identified as CD45.2+, CD3+ and CD4+. Neutrophils were identified as CD45.2+, 
CD11b+ and Ly6G+. Monocytes were identified as CD45.2+, CD11b+ and Ly6C+. 
Following surface staining, cells were fixed with 2% paraformaldehyde in Dulbecco’s 
phosphate buffered saline for 20 min at room temperature, permeabilized with Perm 
wash (BD Biosciences), and then stained with anti-RELMα, biotinylated anti-Ym1, 
APC-conjugated anti-Arg-1 (R&D Systems, Minneapolis, MN), or isotype control 
followed by secondary reagents (Invitrogen). For detection of Ki67 and measurement 
of BrdU incorporation, cells were stained for surface markers, then fixed and 
permeabilized using FoxP3 staining buffer set (eBioscience), and subsequently 
stained with Ki67 set (clone BV56, BD Biosciences) or anti-BrdU (clone BU20a, 
Biolegend) for 30 min at room temperature. Cells were incubated first with or without 
DNase for 30 mins at 37ºC before staining with anti-BrdU antibody. For intracellular 
cytokine staining, lung single cell suspensions were re-stimulated ex vivo in complete 
RPMI1640 media (supplemented with 10% FCS, 2 mM L-glutamine, 100 U/ml 
 8 
penicillin, 100 µg/ml streptomycin) containing 1 µg/ml ionomycin, 500 ng/ml PMA, 
and 10 µg/ml Brefeldin A for 4 hours at 37°C. Following surface staining and fixing, 
cells were intracellularly stained with anti-IL-4 (clone 11B11, Biolegend), IL-13 
(clone eBio13A; eBiosciences), IL-5 (clone TRFK5; Biolegend), and relevant 
isotypes. Expression of RELMα, Ym1, Arg-1, Ki67, IL-4, IL-13, and IL-5 was 
determined relative to isotype control staining. Incorporation of BrdU was determined 
relative to staining of non-DNase treated cells. Live/Dead (Life Technologies) was 
used to exclude dead cells from analysis. Samples were analyzed by flow cytometry 
using Becton-Dickinson FACS LSR II and FlowJo software. 
 
ELISAs 
Quantification of RELMα (PeproTech, Rocky Hill, NJ) and Ym1 (R&D Systems) 
were performed by ELISA in BAL, pleural and peritoneal exudates, as well as in cell 
supernatants of ex vivo cultures of peritoneal or alveolar macrophages. IL-4, IL-5, IL-
13, TNF-α, and IFN-γ (BioLegend and eBioscience) were measured in supernatants 
of ex vivo re-stimulated thoracic lymph node cells and liver homogenates. C1q 
quantification was performed by ELISA (Source BioScience, Nottingham, UK) in 
peritoneal cavity exudates. ELISA assays were performed following manufacturer 
instructions. 
 
Isolation and culture of primary alveolar, peritoneal, and liver macrophages 
Alveolar macrophages were obtained from BAL of mice and rats, and from human 
lung biopsies obtained from patients that were submitted to a lobectomy. An informed 
consent was obtained from all donors. The review board and the ethics committee of 
the Sabadell Hospital approved this study, which was conducted in accordance with 
the guidelines of the World Medical Association’s Declaration of Helsinki. BAL was 
performed with Dulbecco’s phosphate buffered saline with or without 0.2 mM EDTA 
and 0.5% BSA (m/v). Macrophages were purified by adherence for at least 90 min at 
37°C, and 5% CO2 as previously reported (44). Adherent cells were 94.0 ± 1.1 % 
viable (trypan blue exclusion test). Flow cytometry analysis determined that 90 ± 1 % 
of adherent cells isolated from BAL were CD11c and SiglecF positive. To estimate 
the purity of isolated human macrophages, cells were cytospun in a CytoSpin 3 
Cytocentrifuge (Shandon Scientific, Waltham, MA), and the cytospin preparations 
were stained either with anti-CD68 or Diff-Quick kit (Diagnostics Grifols, Barcelona, 
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Spain) following the manufacturer’s protocol. 95 % ± 1.5 % (n=6) of adherent cells 
were macrophages. 
 
Peritoneal macrophages were obtained from mice by washing the peritoneal cavity 
with RPMI 1640 containing 2 mM L-glutamine, 200U/ml penicillin, 100 µg/ml 
streptomycin. For thioglycollate-induced macrophages, mice were injected with 0.4 
ml of 4% Brewer’s thioglycollate (Sigma) for 48–96 h before peritoneal cells were 
harvested. Cells were separated from the lavage fluid by centrifugation (250 x g, 5 
min), resuspended in RPMI 1640 medium (5% heat-inactivated FBS, 100 U/ml  
penicillin, 100 µg/ml  streptomycin, supplemented with glutamine 2 mM), and 
purified by adherence.  Viability of adherent cells was assessed by trypan blue 
exclusion test. Flow cytometry analysis determined that 90 ± 1 % of adherent cell 
isolated from the peritoneal exudate were F4/80 and CD11b positive.  
 
Liver macrophages were isolated from mouse livers as reported previously (45) with 
some modifications. Before collection of the tissue, mice were culled and bled by 
cutting the inferior vena cava. Subsequently the liver was perfused in situ with PBS. 
The liver was then excised and kept in HBSS. Subsequently, the organ was minced to 
small pieces and digested with collagenase B (0.2 mg/ml), collagenase D (0.4 mg/ml) 
(Roche) and 80 U/ml DNase (Life Technologies, Carlsbad, California) in HBSS at 
37°C for 30 minutes. Digested tissue was filtered through a cell strainer (70 µm) to 
prepare a single cell suspension. The filtrate was centrifuged twice at 300xg (4°C) for 
5 min to wash out the residual enzymatic solution. The pellet was resuspended and 
centrifuged at 50xg (4°C) for 3 min to separate non-parenchymal from parenchymal 
cells. The pellet containing parenchymal cells was discarded. The supernatant was 
centrifuged again at 300xg for 5 min. The cell pellet was seeded on 96-well culture 
plates in complete culture medium [RPMI 1640 medium (10% heat-inactivated FBS, 
100 U/ml penicillin, 100 µg/ml streptomycin, supplemented with glutamine 2 mM)]. 
Following incubation for 2 h in a humidified atmosphere of 95% air with 5% carbon 
dioxide (CO2) at 37°C, the cells were gently washed with fresh culture medium. 
Viability of adherent cells was assessed by trypan blue exclusion test. Flow cytometry 
analysis determined that 70 ± 5 % of adherent cells isolated from the liver 
homogenates were F4/80 and CD11b positive. 
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In vitro stimulation of macrophages 
Macrophages were pre-cultured for 24 h in RPMI 1640 medium with 5% FBS. 
Subsequently, cells were treated with IL-4 (0.5-1 µg/ml) (ImmunoTools, Berlin, 
Germany) and/or SP-A (25, 50 and 100 µg/ml) or native human C1q (10 and 100 
µg/ml). The following blocking antibodies were added 2 hours before stimulation: 10 
µg/ml of anti-Myo18A (16), 10-50 µg/ml anti-SIRPα (eBioscience), and 10-50 µg/ml 
anti-calreticulin (Thermo Scientific). Under these conditions cell viability was higher 
than 97%. Macrophage cultures were plated in triplicate wells and each series of 
experiments was repeated at least three times. 
 
Cell proliferation assays  
For 5–ethynyl–2′–deoxyuridine (EdU)/BrdU incorporation analysis, cells were treated 
with IL-4, SP-A, C1q and combinations thereof for 24 hours. Then, cells were 
exposed to 10 µM EdU/BrdU for another 24 hours. For confocal microscopy analysis 
of EdU incorporation, cells were fixed with 2% formaldehyde for 15 minutes at room 
temperature and permeabilized with 0.2% saponin in PBS. EdU was detected with 
Alexa Fluor 647-azide using Click-iT EdU assay kit (Life Technologies). Sequential 
double immunostaining was performed with a monoclonal antibody to CD11c (AbD 
Serotec, Kidlington, UK), and immune complexes were visualized with FITC-
conjugated secondary antibody (Invitrogen). Micrographs were taken with a Leica 
TCS SP2 Confocal System. Flow cytometry analysis of BrdU and Ki67 expression 
was performed as described above. 
 
Arginase activity assay  
Arginase activity was measured as previously reported (46). Briefly, rat alveolar 
macrophages were lysed with 50 µl of 50 mM Tris–HCl pH 7.5, Triton X-100 0.1 %, 
1 mM benzamidine, 200 µg/ml aprotinin, and 200 µg/ml leupeptin. After 30 min 
shaking at 4ºC, arginase was activated with 50 µl of 10 mM MnCl2 and 50 mM Tris-
HCl, pH 7.5, for 10 min at 55º C. L-arginine hydrolysis was measured by incubating 
the cell lysate with 25 µl of 0.5 M L-arginine (Sigma) (pH 9.7) at 37ºC for 1 h. The 
reaction was stopped by addition of 200 µl H2SO4 /H3PO4 /H2O (1:3:7 v/v). The 
produced urea was quantified at 570 nm after addition of 25 µl of α-
isonitrosopropiophenone (dissolved in 100% ethanol) followed by heating at 99ºC for 
45 min. Urea production was normalized to cell number for each treatment by 
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quantifying cells with the WST-1 reagent (Roche), following manufacturer’ 
instructions. One unit of arginase activity is defined as the amount of enzyme that 
catalyses the formation of 1 µmol urea per min. 
 
 siRNA-mediated gene-silencing effects in vitro 
After isolation, primary alveolar macrophages were resuspended in Amaxa® mouse 
macrophage nucleofector solution (Lonza) and nucleofected with 100 nM siRNA 
using a nucleofector 2b device (Lonza). Experiments were conducted using two 
Stealth siRNAs directed against rat Myo18A (RSS322720 and RSS322721) (Applied 
Biosystems, Carlsbad, California). Medium GC Stealth siRNA was used as control 
(12935300) (Applied Biosystems). Myo18A expression was detected by Western blot 
analysis with an anti-Myo18A antibody (16). After 48 hours post nucleofection, 
Myo18A expression was reduced 72 ± 4% for RSS322720 and 71 ± 5% for 
RSS322721 compared to control. At this time-point, cells were stimulated. 
 
Statistics  
Normal distribution of data was determined by visual examination of residuals. 
Statistical evaluation of different groups was performed either by analysis of variance 
(ANOVA) followed by the Bonferroni multiple comparison test or by unpaired two-
tailed Student’s t-test, as indicated. An α level ≤ 5% (p ≤ 0.05) was considered 
significant. All statistical calculations were performed using PRISM, (Graphpad, La 
Jolla, CA). 
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Fig. S1. Further characterization of WT vs. SP-A-deficient mice during Nippostrongylus 
brasiliensis infection. WT or SP-A-/- mice were left uninfected or infected with 250 N. brasiliensis 
L3’s, and assessed at day 6 after infection. (A) SP-A mRNA expression in lung tissue of WT and IL-
4Rα-/- mice. (B) Egg output in faeces form WT and SP-A-/- mice. Expression of (C) Ym1 and (D) Arg 
by aMφ . (E) Analysis of secreted RELMα and Ym1 from BAL by ELISA. (F) Number of alveolar 
macrophages recovered in BAL. (G) Levels of IL-4, IL-13, IL-5, TNFα, and IFN-γ in supernatants of 
thoracic lymph node cells from WT and SP-A-/- mice, cultured with N. brasiliensis antigen (1 µg/ml); 
results are normalized to those obtained for cells cultured with medium alone. (H) Expression of IL-13 
and IL-5 by ILC2 and IL-4, IL-13 and IL-5 by CD4+ cells from single-cell suspensions of lung tissue 
stimulated ex vivo with PMA and ionomycin. (I) Amplification of Il13, Il5 and Tnf-encoding mRNA in 
lung homogenates is also shown. Results are representative from two independent experiments (means 
± SEM) (naïve: 3 mice, Nb: 6 mice). ANOVA followed by the Bonferroni multiple-comparison test or 
Student’s t-test (F) was used. *p < 0.05 , **p < 0.01 and ***p < 0.001, when compared with the 
uninfected group; °p < 0.05, °°p < 0.01 and °°°p < 0.001 when WT vs. SP-A-/- infected groups are 
compared.  
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Fig. S2. Characterization of alveolar macrophages from SP-A-deficient mice. (A) Sequential 
identification of aMφs by flow cytometry. Cells first identified by size (1), and then as singlets (2) and 
live cells (3). Subsequently, hematopoietic cells were selected by CD45.2 expression (4). Lin− cells (5) 
were obtained by gating out CD3+, CD19+, Ly6G+, and Ter119+ cells (T cells, B cells, neutrophils 
and red blood cells, respectively). Monocytes were successively excluded by expression of Ly6C (6). 
Lin− and Ly6C− populations were further subgated on the basis of the expression of CD11c versus 
SiglecF. aMφ are identified as CD11chi and SiglecFhi  (7); a representative population of aMφ from WT 
and SP-A-deficient mice is shown. The expression of MHCII and CD11b by aMφs is also shown for 
both strains.  All shown gates are children of the parent gates shown previously. (B) Number and 
percentage of aMφ recovered in BAL. (C) Expression of MHCII, SiglecF, CD11c and CD11b in aMφ 
from WT and SP-A-deficient mice. Data are representative from two independent experiments (mean ± 
SEM; WT: 4 mice, SP-A-/-: 3 mice).  Student’s t-test was used. (D) Purified aMφ from WT and SP-A-
deficient mice were treated with or without IL-4 (1µg/ml) and exposed to BrdU for proliferation 
analysis. BrdU incorporation and secretion of Ym1 by resident aMφ are shown. The results are 
presented as means (± SEM) from two different cell cultures with at least three biological replicates. 
ANOVA followed by the Bonferroni multiple-comparison test was used. *p < 0.05, **p < 0.01, and 
***p < 0.001, when compared with untreated macrophages. 
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Fig. S3. Alveolar macrophages from SP-A-deficient mice show decreased IL-4-induced 
proliferation and M(IL-4) activation. WT and SP-A-/- mice were treated with 5µg of IL-4c (i.p.) at 
days 0 and 2; and samples were analyzed at day 4. (A) Ym1 and (B) Ki67 expression in aMφ in 
response to IL-4c. In (C) a representative FACS plot from WT and SP-A-/- mice is shown to 
demonstrate overlap between BrdU+ and Ki67+ cells treated with PBS or IL-4c (Ki67 green contour 
and BrdU+ cells blue dots). (D) Protein levels of RELMα and Ym1 in BAL measured by ELISA. (E) 
Expression of IL-4Rα by aMφ from BAL. Data were pooled from three independent experiments 
(means ± SEM) (PBS: 9 mice, IL-4c: 11 mice). ANOVA followed by the Bonferroni multiple-
comparison test was used. *p < 0.05, **p < 0.01, and ***p < 0.001 when compared with the untreated 
group. °p < 0.05, °°p < 0.01 and °°°p < 0.001 when WT vs. SP-A-/- groups are compared. 
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Fig. S4. Proliferation and activation of macrophages isolated from mice, humans, and rats. (A) 
Purified alveolar (BAL-Mφ), peritoneal [resident (P-Mφ)] and thioglycollate-recruited (Thio-Mφ) from 
mice were treated with or without IL-4 (0.5-1 µg/ml). Ki67, RELMα, and Ym1 expression was 
assessed by FACS.  Note: cultured aMφ are Ym1+ regardless of IL-4 treatment. Purified aMφ from 
mice (B), humans (C), or rats (D) were treated with or without IL-4 (0.5-1 µg/ml) in the presence or 
absence of SP-A. (B) BrdU incorporation and secretion of Ym1 by cultured aMφ from WT and IL-
4Rα-/- mice in the presence and absence of SP-A. (C) MKI67 and MRC1 mRNA expression by human 
aMφ as measured by qRT-PCR. (D) EdU incorporation analyzed by flow cytometry and arginase 
activity of rat aMφ. A representative confocal micrograph of rat aMφ immuno-stained with CD11c-
FITC and EdU-Alexa Fluor 647 is shown. Numbers below indicate percentage ± SEM of EdU+ cells 
from three independent experiments. The results are presented as means (± SEM) from three different 
cell cultures with at least three biological replicates. ANOVA followed by the Bonferroni multiple-
comparison test was used. *p < 0.05, **p < 0.01, and ***p < 0.001, when compared with untreated 
macrophages; οp < 0.05, °°p < 0.01, and °°°p < 0.001, when SP-A+IL-4-treated macrophages were 
compared with IL-4-treated macrophages.  
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Fig. S5. C1q protein levels in the peritoneal cavity and characterization pMφ  of from C1q-
deficient mice. (A) Following IL-4c delivery, C1q protein was measured by ELISA in WT mice. (B) 
Sequential identification of pMφ by flow cytometry. Cells first identified by size (1), and then as 
singlets (2) and live cells (3). Subsequently, hematopoietic cells were selected by CD45.2 expression 
(4). Lin− cells (5) were obtained by gating out CD3+, CD19+, Ly6G+ and SiglecF+ cells (T cells, B 
cells, neutrophils and eosinophils, respectively). Monocytes and dendritic cells were successively 
excluded by expression of Ly6C and CD11c (6). Lin−, CD11c− and Ly6C− populations were further 
subgated on the basis of the expression of CD11b versus F4/80. pMφ are CD11bhi and F4/80hi (7); a 
representative population of pMφs from WT and C1q-deficient mice is shown. The expression of 
CD102 and Gata6 by pMφs is also shown for both strains.  All shown gates are children of the parent 
gates shown previously. (C) Number and percentage of pMφ recovered in the peritoneal washes. (D) 
Expression of CD11b, F4/80, CD102, Gata6, and IL-4Rα in pMφ from WT and C1q-deficient mice. 
Data are representative from two independent experiments (mean ± SEM; WT: 4 mice, C1qa-/-: 4 
mice). In C and D, Student’s t-test was used. In E and F, purified pMφ from WT and C1q-deficient 
mice were treated with or without IL-4 (1 µg/ml or 10 ng/ml) in the presence or absence of C1q, and 
exposed to BrdU. (E) Proliferation (BrdU incorporation and Ki67 expression) in response to 1 µg/ml of 
IL-4. (F) M(IL-4) activation (RELMα and Ym1 expression) of pMφs in response to 10 ng/ml of IL-4. 
The data shown are means ± SEM of two different pMφ cultures with at least three biological 
replicates. ANOVA followed by the Bonferroni multiple-comparison test was used. **p < 0.01, and 
***p < 0.001, when compared with untreated cells (C); ° p < 0.05, °°p < 0.01, and °°°p < 0.001, when 
C1q+IL-4-treated macrophages were compared with IL-4-treated macrophages. 
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Fig. S6. (A-C) Myo18A mediates SP-A’s effects on aMφs isolated from humans and rats. (A) 
Purified rat aMφ were treated with either anti-Myo18A (10 µg/ml), anti-calreticulin (10-50 µg/ml ), 
anti-SIRPα (10-50 µg/ml), or an isotype control for two hours. Next, cells were IL-4-stimulated with or 
without native SP-A. (B) mRNA expression of MKI67 and MRC1 by human aMφ treated with anti-
Myo18A antibody. (C) BrdU incorporation and arginase activity in rat aMφ that were nucleofected 
with Myo18A (RSS322720) or control siRNA. Similar results were found using RSS322721 Myo18A 
siRNA. (D) The collagen-like domain of SP-A is required for functional interaction with Myo18A 
on aMφ . Purified rat aMφ were IL-4-stimulated with or without either native human SP-A or 
recombinant human SP-A1 expressed in insect cells (SP-A1hyp). Recombinant human SP-A1 expressed 
in insect cells lacks the prolyl hydroxylation, resulting in improper folding of the collagen domain (31). 
The data shown are means ± SEM of three different alveolar or pMφ cultures with at least three 
biological replicates. ANOVA followed by the Bonferroni multiple-comparison test was used. **p < 
0.01, and ***p < 0.001, when compared with untreated cells (C); °p < 0.05, and °°°p < 0.001, when 
SP-A+IL-4-treated macrophages were compared with IL-4-treated macrophages; ##p < 0.01, and ###p 
< 0.001, when either the effect of Myo18A siRNA vs. control siRNA or anti-Myo18A vs. rabbit IgG 
are compared or when the effects of native SP-A vs. SP-A1hyp on macrophage activation and 
proliferation are compared.  
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Fig. S7. Myo18A expression in response to IL-4 treatment and further characterization of 
blocking Myo18A on IL-4-mediated activation of macrophages in vivo. Time-dependent expression 
of Myo18A on the cell surface of alveolar (A) and peritoneal (B) macrophages in response to IL-4 
treatment in vitro. The data shown are means ± SEM of three different aMφ or pMφ cultures with at 
least three biological replicates. ANOVA followed by the Bonferroni multiple-comparison test was 
used. *p < 0.05, and ***p < 0.001, when compared with 0 hours post IL-4 stimulation. (C-D) For 
aMφs, 5 µg IL-4c was delivered ip at day 0 and day 2, and BAL cells analyzed at day 4. For pMφs, 1 
µg IL-4c was delivered ip at day 0, and peritoneal cells analyzed at day 1: Myo18A expression on the 
surface of macrophages from WT, SP-A-/-, and C1qa-/- mice treated with or without IL-4c. (E) For 
aMφs, mice were treated as in (C-D) and simultaneously, animals were intra-nasally treated with either 
anti-Myo18A or rabbit IgG at day 2 and 3, and lung samples were analyzed at day 4. (F) Alternatively, 
for pMφs, mice were also treated as in (C-D) with concomitant delivery of anti-Myo18A or rabbit IgG 
(ip) 2 hours before IL-4c administration. Concentration of RELMα and Ym1 in BAL (E) and the 
peritoneal cavity (PC) (F) are shown. Data were pooled from three independent experiments (means ± 
SEM) (PBS: 6 mice, other groups: 9 mice). ANOVA followed by the Bonferroni multiple-comparison 
test was used. *p < 0.05, **p < 0.01, and ***p < 0.001, when compared with PBS treated mice; °°p < 
0.01, and °°°p < 0.001 when anti-Myo18A vs rabbit IgG treatment is compared in IL-4c-treated mice.  
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Fig. S8. Further characterization of WT , IL-4Rα and C1q-deficient mice in a model of peritoneal 
dyalisis. WT, C1qa-/- or IL-4Rα-/- mice were either untreated (control, C) or treated with 14 ip 
injections of Dianeal PD-4 every other day. Samples were analyzed a day after the last delivery. 
Amplification of (A) Col3a1, (B) Vegf, and (C) Mmp12- encoding mRNA in peritoneal tissue. (D) 
Percentage of infiltrating monocytes as quantified by FACS. Results are representative from two 
independent experiments (means ± SEM) (untreated: 3 mice, PD4: 6 mice). ANOVA followed by the 
Bonferroni multiple-comparison test or Student’s t-test (A) was used. *p < 0.05, **p < 0.01, and ***p 
< 0.001 when compared with control group; °p < 0.05 and °°°p < 0.001 when WT vs. C1qa-/- mice 
treated with Dianeal PD-4 are compared.  
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Fig. S9. Lactate-dependent proliferation and type 2 macrophage activation requires stabilization 
of HIF1α in a model of peritoneal dialysis. Hif1aflox/flox;LysMcre+/−˗ mice and littermate WT controls 
(Hif1aflox/flox;LysMcre−/−) were either untreated (control, C) or treated with 5 ip injections of Dianeal 
PD-4 every other day. Samples were analyzed a day after the last delivery. (A) BrdU incorporation in 
pMφ. (B) Ki67expression. (C) Ym1 and (D) RELMα expression. (E) Amplification of C1qa-encoding 
mRNA in peritoneal tissue. (F) Myo18A expression on the surface of peritoneal macrophages. Results 
are representative from two independent experiments (means ± SEM) (untreated: 3 mice, PD4: 4 mice). 
ANOVA followed by the Bonferroni multiple-comparison test or Student’s t-test (A) was used. *p < 
0.05, **p < 0.01, and ***p < 0.001 when compared with control group; °p < 0.05, °°p < 0.01, and °°°p 
< 0.001 when WT vs. myeloid specific HIF-1α-deficient mice treated with Dianeal PD-4 are compared. 
(G) Schematic of lactate-dependent promotion of a type 2 macrophage phenotype, which is 
dependent on HIF1α  and C1q in the peritoneal cavity. A lactate-based dialysate increases C1q 
levels in the peritoneal cavity and expression of myosin 18A on the surface of pMφ. Dialysate-induced 
proliferation of pMφ and production of type 2 macrophage markers were blocked in C1q deficiency 
mice and animals lacking HIF1α in macrophages, but not in IL-4Rα deficient mice. The data suggests 
that C1q is required to amplify HIF1α-dependent lactate signaling, which promotes peritoneal fibrosis. 
(MCT: monocarboxylate transporter for lactate; HIF1α: hypoxia-inducible factor 1α) 
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Fig. S10. IL-4 mediated proliferation and activation of pleural cavity macrophages is not 
enhanced by C1q. WT and C1qa-deficient mice were treated with 1µg of IL-4c (ip) at day 0; and 
samples were analyzed at day 1. Proliferation (BrdU incorporation and Ki67 expression) and M(IL-4) 
activation (RELMα expression) of resident pMφ are shown. Data were pooled from two independent 
experiments (means ± SEM) (PBS: 8 mice, IL-4c: 10 mice). ANOVA followed by the Bonferroni 
multiple-comparison test was used. ***p < 0.001 when compared with the untreated group. 
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Fig. S11. Characterization of liver macrophages from C1q-deficient mice. (A) Sequential 
identification of liver macrophages by flow cytometry. Cells were first identified by size (1), and then 
as singlets (2) and live cells (3). Subsequently, hematopoietic cells were selected by CD45.2 expression 
(4). Lin− cells (5) were obtained by gating out CD3+, CD19+, Ly6G+ and SiglecF+ cells (T cells, B 
cells, neutrophils and eosinophils, respectively). Monocytes and dendritic cells were successively 
excluded by expression of Ly6C and CD11c (6). Lin−, CD11c− and Ly6C− populations were further 
subgated on the basis of the expression of CD11b versus F4/80. CD11b+ and F4/80+ cells are liver 
macrophages (7); a representative population of liver macrophages from WT and C1q-deficient mice is 
shown. The expression of MHCII and CD11b by liver macrophages is also shown for both mice 
strains.  All shown gates are children of the parent gates shown previously. (B) Number and (C) 
percentage of liver macrophages from tissue homogenates. Expression of (D) F4/80, (E) CD11b, (F) 
MHCII, and (G) IL-4Rα in liver macrophages from WT and C1q-deficient mice. Data are 
representative of two independent experiments (mean ± SEM; WT: 4 mice, C1qa-/-: 4 mice). Student’s 
t-test was used. 
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Fig. S12. Myo18A mediates C1q enhancement of IL-4-induced effects on liver macrophages. 
Purified mouse liver macrophages were treated with anti-Myo18A or rabbit IgG for one hour. Next, 
cells were IL-4-stimulated with or without C1q. Proliferation (BrdU incorporation and Ki67 
expression) and M(IL-4) activation (RELMα and Ym1 expression) of liver macrophages are shown. 
The results are presented as means (± SEM) from three different cell cultures with at least three 
biological replicates. ANOVA followed by the Bonferroni multiple-comparison test was used. **p < 
0.01, and ***p < 0.001, when compared with untreated cells; °p < 0.05 and °°°p < 0.001, when 
C1q+IL4-treated macrophages were compared with IL-4-treated macrophages; #p < 0.05, and ###p < 
0.001, when the effect of anti-Myo18A antibody is compared in cells treated with C1q+IL4. 
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Fig. S13. Further characterization of WT vs. C1qa-deficient mice during Listeria monocytogenes 
infection. WT, C1qa-/-, or IL-4Rα-/- mice were left uninfected or received intravenous infection with 
104 L. monocytogenes c.f.u. and samples were assessed at day 3.5 after infection. (A) Expression of 
Ym1 by liver macrophages. (B) Ki67 expression by liver macrophages. (C) Levels of IL-4 and IL-13 in 
the supernatants of liver homogenates from WT, C1qa-/-, and IL-4Rα-/- mice. (D-E) iNOS expression 
by liver monocytes and macrophages. (C) Levels of TNFα and IFN-γ in the supernatants of liver 
homogenates from WT, C1qa-/-, and IL-4Rα-/- mice. Data are representative from two independent 
experiments (mean ± SEM; naïve: 4 mice, Lm: 4-6 mice). ANOVA followed by the Bonferroni 
multiple-comparison test was used. *p < 0.05, **p < 0.01 and ***p < 0.001, when compared with the 
uninfected group; °p < 0.05, °°p < 0.01, and °°°p < 0.001 when WT vs. C1qa-/- or IL-4Rα-/- infected 
groups are compared. 
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Fig. S14. Schematic of direct and indirect effects of IL-4. Rather than IL-4 (or IL-13) signaling to 
macrophages alone, IL-4 drives the production of a second signal for full M(IL-4) activation and 
proliferation. (A) IL-4 increases the production of SP-A by alveolar epithelial type II cells (AEC2) and 
the expression of myosin 18A on the surface of aMφ. SP-A deficiency or receptor blockade abrogated 
IL-4-induced proliferation of aMφ and reduced M(IL-4) activation. (B) In the liver and the peritoneal 
cavity, IL-4 increases the production of C1q and the expression of myosin 18A receptor on the surface 
of liver and peritoneal macrophages. C1q deficiency or receptor blockade impedes full M(IL-4) 
activation and proliferation.   
 
  
 26 
 
Supplementary Table 1. Genotyping of the Sftpa1-/- and Sftpa1+/+ littermates 
SP-A-deficient mice genotyping 
Primer Sequence   
Sftpa1 F neo  GTGGGGTGGGATTAGATAAATGC 
Sftpa1 1743-1766  GCATTAGACGACAGAACTCCAGCC 
Sftpa1 R 1981-
1957  TACTGAGAGATGTGTGCTTGGTGAG 
 
 
Supplementary Table 2. Primer sequences used for quantitative RT-PCR of genes of 
interest.  
Gene Primer Sequence 
Sftpa1 
  
For CTGGAGAACATGGAGACAAGG 
Rev AAGCTCCTCATCCAGGTAAGC 
Col3a1 
  
For AAGGGTGAAGTCGGTGCTC 
Rev TCCAGCTCCACCTCTAGCA 
Col1a1 
  
For TCTGGTCTCCAGGGTCCTC 
Rev GTCTTTGCCAGGAGAACCAG 
Acta2 
  
For CCAACCGGGAGAAAATGAC 
Rev CAGTTGTACGTCCAGAGGCATA 
Vegf 
  
For ACTCGGATGCCGACACGGGA 
Rev CCTGGCCTTGCTTGCTCCCC 
Mmp12 
  
For CAATTGGAATATGACCCCCTGT 
Rev AGCAAGCACCCTTCACTACAT 
Rpl13a 
  
For CATGAGGTCGGGTGGAAGTA 
Rev GCCTGTTTCCGTAACCTCAA 
Rn18s 
  
For GTAACCCGTTGAACCCCATT 
Rev CCATCCAATCGGTAGTAGCG 
MKI67 
  
For TCGACCCTACAGAGTGCTCA 
Rev GTGGGGAGCAGAGGTTCTTC 
MRC1 
  
For CAGATGCCCGGAGTCAGATC 
Rev TTTATCCACAGCCACGTCCC 
GAPDH 
  
For GATCATGAGCAATGCCTCCT 
Rev TGTGGTCATGAGTCGTTCCA 
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